Teva announces largest-ever trial to collect information from patients and physicians about td, its impact and progression over time, and evaluate treatment-related outcomes

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the initiation of a 3-year longitudinal registry and study to assess the impact of tardive dyskinesia (td) and real-world treatment patterns and outcomes. the phase 4, multicenter, prospective, observational two-part study is the largest-ever study of its kind for td and will collect information from both patients and physicia
TEVA Ratings Summary
TEVA Quant Ranking